

Table 1.21
U.S. Prevalence Counts, Invasive Cancers Only, January 1, 2018^a
Using Different Tumor Inclusion Criteria^b

Site	Sex	5-Year Limited Duration			26-year Limited Duration	
		1st Invasive Tumor Ever ^c	1st Per Site in Previous 26 Years ^d	1st Per Site in Previous 5 Years ^e	1st Invasive Tumor Ever ^c	1st Per Site in Previous 26 Years ^d
All Sites	Both Sexes	4,880,121	5,050,887	5,593,196	14,419,319	14,915,902
	Male	2,378,282	2,435,676	2,705,061	6,982,721	7,134,746
	Female	2,501,839	2,615,211	2,888,135	7,436,598	7,781,156
Oral Cavity & Pharynx	Both Sexes	123,575	147,227	152,996	312,390	354,830
	Male	89,094	104,227	107,930	216,952	243,022
	Female	34,481	43,000	45,066	95,438	111,808
Esophagus	Both Sexes	22,707	28,561	28,734	39,975	48,079
	Male	18,122	22,446	22,560	31,401	37,428
	Female	4,585	6,115	6,174	8,574	10,651
Stomach	Both Sexes	45,793	54,879	55,846	96,886	112,569
	Male	26,723	32,118	32,507	55,172	63,993
	Female	19,070	22,761	23,339	41,714	48,576
Colon & Rectum	Both Sexes	399,424	461,307	469,550	1,134,250	1,272,980
	Male	207,974	238,379	242,731	580,992	645,984
	Female	191,450	222,928	226,819	553,258	626,996
Liver & Intrahepatic Bile Duct	Both Sexes	53,795	62,920	63,305	81,772	93,247
	Male	38,455	44,554	44,839	58,224	65,633
	Female	15,340	18,366	18,466	23,548	27,614
Pancreas	Both Sexes	47,649	59,939	60,010	65,973	81,172
	Male	24,303	30,509	30,544	33,041	40,627
	Female	23,346	29,430	29,466	32,932	40,545
Larynx	Both Sexes	28,391	34,454	34,947	76,081	87,212
	Male	23,247	28,028	28,445	62,231	70,977
	Female	5,144	6,426	6,502	13,850	16,235
Lung & Bronchus	Both Sexes	248,933	328,150	340,962	423,209	543,260
	Male	112,552	149,779	154,619	184,864	237,505
	Female	136,381	178,371	186,343	238,345	305,755
Melanoma of the Skin	Both Sexes	316,066	371,450	394,522	995,989	1,115,391
	Male	174,737	209,450	225,195	519,840	589,435
	Female	141,329	162,000	169,327	476,149	525,956
Breast	Female	955,157	1,053,306	1,118,496	3,096,156	3,361,799
Cervix	Female	41,149	43,646	43,844	182,868	192,459
Corpus & Uterus, NOS	Female	213,645	240,805	241,088	632,326	699,551
Ovary ^f	Female	61,640	70,244	70,335	167,758	190,297

^a U.S. 2018 cancer prevalence counts are based on 2018 cancer prevalence proportions from the SEER 13 registries (not including the Alaska Natives Registry) and 1/1/2018 U.S. population estimates based on the average of 2017 and 2018 population estimates from the U.S. Bureau of the Census.

^b Prevalence estimates are ambiguous for those with multiple cancers, unless the tumor inclusion criteria are understood. Depending on the application, different inclusion criteria may be appropriate. This table provides three different methods of tumor inclusion:

^c (c) First invasive tumor ever

^d (d) First invasive tumor for each cancer site diagnosed during the previous 26 years (1992-2017)

^e (e) First invasive tumor for each cancer site diagnosed during the previous 5 years (2013-2017)

For definitions (d) and (e) all sites is treated as a separate cancer "site".

Consider a woman who had three invasive cancers: Melanoma in 1981; Breast cancer in 2011; Melanoma in 2012.

In method (c) the melanoma is the woman's first cancer, and is counted for the melanoma and all sites 26-year limited duration prevalence. For 5-year limited duration prevalence, the woman is not counted at all since her first cancer occurred more than 5 years prior to 1/1/2018.

In method (d) the 1981 melanoma is counted for the melanoma and all sites 26-year limited duration prevalence. The 2011 breast cancer is counted for the breast 5-year and 26-year limited duration prevalence.

In method (e) the 2011 breast cancer is counted for the breast cancer and all sites 5-year limited duration prevalence. The 2012 melanoma is counted for 5-year limited duration prevalence for melanoma.

^f Ovary excludes borderline cases or histologies 8442, 8451, 8462, 8472, and 8473.

Table 1.21 - continued
 U.S. Prevalence Counts, Invasive Cancers Only, January 1, 2018^a
 Using Different Tumor Inclusion Criteria^b

Site	Sex	5-Year Limited Duration			26-year Limited Duration	
		1st Invasive Tumor Ever ^c	1st Per Site in Previous 26 Years ^d	1st Per Site in Previous 5 Years ^e	1st Invasive Tumor Ever ^c	1st Per Site in Previous 26 Years ^d
Prostate	Male	848,271	925,831	925,944	3,017,103	3,216,087
Testis	Male	45,457	46,348	46,918	197,380	201,333
Urinary Bladder	Both Sexes	206,551	262,551	269,110	555,999	666,514
	Male	159,177	202,966	208,207	421,030	504,748
	Female	47,374	59,585	60,903	134,969	161,766
Kidney & Renal Pelvis	Both Sexes	179,670	219,423	223,467	451,550	532,888
	Male	113,525	139,334	142,065	276,850	327,963
	Female	66,145	80,089	81,402	174,700	204,925
Brain & Nervous System	Both Sexes	45,116	48,855	49,316	129,633	135,594
	Male	24,479	26,587	26,865	68,587	71,585
	Female	20,637	22,268	22,451	61,046	64,009
Thyroid	Both Sexes	203,921	230,954	231,660	660,323	724,365
	Male	47,921	56,780	56,975	143,367	162,275
	Female	156,000	174,174	174,685	516,956	562,090
Hodgkin Lymphoma	Both Sexes	34,619	37,258	37,283	151,373	157,887
	Male	19,074	20,680	20,688	79,452	82,850
	Female	15,545	16,578	16,595	71,921	75,037
Non-Hodgkin Lymphoma	Both Sexes	218,558	260,111	265,977	615,513	699,378
	Male	118,252	141,099	144,166	327,916	372,109
	Female	100,306	119,012	121,811	287,597	327,269
Myeloma	Both Sexes	72,752	86,937	87,460	126,684	147,663
	Male	40,442	48,917	49,291	69,683	82,159
	Female	32,310	38,020	38,169	57,001	65,504
Leukemia	Both Sexes	137,850	164,784	165,287	373,716	422,183
	Male	80,968	97,034	97,350	215,372	243,137
	Female	56,882	67,750	67,937	158,344	179,046
Acute Lymphocytic Leukemia	Both Sexes	20,174	21,068	21,084	76,226	77,711
	Male	11,454	11,904	11,912	42,622	43,296
	Female	8,720	9,164	9,172	33,604	34,415
Childhood (Ages 0-19)	Both Sexes	70,886	71,020	71,510	293,997	294,727
	Male	37,593	37,665	37,938	154,711	155,080
	Female	33,293	33,355	33,572	139,286	139,647
Kaposi Sarcoma	Both Sexes	7,006	7,607	7,607	33,086	34,867
	Male	6,406	6,885	6,885	31,467	33,007
	Female	600	722	722	1,619	1,860
Mesothelioma	Both Sexes	3,263	4,303	4,303	4,768	6,044
	Male	2,274	3,004	3,004	2,991	3,853
	Female	989	1,299	1,299	1,777	2,191

^a U.S. 2018 cancer prevalence counts are based on 2018 cancer prevalence proportions from the SEER 9 registries and 1/1/2018 U.S. population estimates based on the average of 2017 and 2018 population estimates from the U.S. Bureau of the Census.

^b Prevalence estimates are ambiguous for those with multiple cancers, unless the tumor inclusion criteria are understood. Depending on the application, different inclusion criteria may be appropriate. This table provides three different methods of tumor inclusion:

^c (c) First invasive tumor ever
^d (d) First invasive tumor for each cancer site diagnosed during the previous 26 years (1992-2017)
^e (e) First invasive tumor for each cancer site diagnosed during the previous 5 years (2013-2017)
 For definitions (d) and (e) all sites is treated as a separate cancer "site".

Consider a woman who had three invasive cancers: Melanoma in 1981; Breast cancer in 2011; Melanoma in 2012.

In method (c) the melanoma is the woman's first cancer, and is counted for the melanoma and all sites 26-year limited duration prevalence. For 5-year limited duration prevalence, the woman is not counted at all since her first cancer occurred more than 5 years prior to 1/1/2018. In method (d) the 1981 melanoma is counted for the melanoma and all sites 26-year limited duration prevalence. The 2011 breast cancer is counted for the breast 5-year and 26-year limited duration prevalence. In method (e) the 2011 breast cancer is counted for the breast cancer and all sites 5-year limited duration prevalence. The 2012 melanoma is counted for 5-year limited duration prevalence for melanoma.